论文部分内容阅读
目的初步探讨吉非替尼(Iressa)联合5-FU对HER1高表达胃癌细胞的生长抑制作用。方法以Her-1基因高表达的胃癌细胞株SGC7901为研究对象,以MTT法检测两药物各自及合用时对胃癌细胞株增殖影响的抑制率;流式细胞仪检测细胞周期变化和凋亡;以RT-PCR分析药物对靶蛋白酶mRNA的影响。结果吉非替尼可增强化疗药对HER-1阳性胃癌细胞的毒性作用。先吉非替尼和5-FU联合再序贯使用分子靶向药吉非替尼的方案效果最佳;联合方案对细胞周期的改变影响明显;同时吉非替尼能增强5-FU对胸苷酸合成酶(TSmRNA)表达的抑制。结论吉非替尼联合5-FU对Her-1/EGFR过表达胃癌细胞有明显的杀伤性增强作用而且存在最佳联合方案。
Objective To investigate the inhibitory effect of gefitinib combined with 5-FU on the growth of HER1-overexpressing gastric cancer cells. Methods The gastric cancer cell line SGC7901 with high expression of Her-1 gene was used as the research object. The inhibition rate of the proliferation of gastric cancer cell lines was detected by MTT assay. The cell cycle and apoptosis were detected by flow cytometry. The effect of the drug on the target protease mRNA was analyzed by RT-PCR. Results Gefitinib enhanced the toxicity of chemotherapeutic drugs on HER-1 positive gastric cancer cells. Gefitinib and 5-FU combined sequential use of molecular targeted drugs gefitinib best effect; combination of the program significantly affect the cell cycle changes; while gefitinib can enhance 5-FU on the chest Inhibition of the expression of nucleotide synthase (TSmRNA). Conclusion Gefitinib combined with 5-FU has obvious cytotoxicity on Her-1 / EGFR overexpressing gastric cancer cells and there is an optimal combination regimen.